Drug intelligence / Profile preview

everolimus + rituximab

Development stage: Unknown
Lead developer: Novartis
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

A combination therapy consisting of everolimus, an oral mTOR inhibitor, and rituximab, a monoclonal antibody targeting CD20 on B-cells. This combination has been studied for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Everolimus inhibits mTOR signaling, blocking cell cycle progression and inducing growth arrest, while rituximab promotes B-cell lysis through complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity.

Targets

CD20 (B-lymphocyte antigen CD20)mTOR (Mammalian target of rapamycin kinase)

Beyond the preview

Go deeper on everolimus + rituximab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on everolimus + rituximab.

Explore the full profile